{"pmid":32281679,"title":"COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy.","text":["COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy.","Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has spread worldwide triggering a pandemic. Its first case was reported in Wuhan, the capital of China's Hubei province, and since then it has spread across world becoming one of the worst pandemics in the history of mankind(1) . Its basic reproductive number (R0 ) has been determined to be 2-3(2) . This article is protected by copyright. All rights reserved.","J Med Virol","Syal, Kirtimaan","32281679"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has spread worldwide triggering a pandemic. Its first case was reported in Wuhan, the capital of China's Hubei province, and since then it has spread across world becoming one of the worst pandemics in the history of mankind(1) . Its basic reproductive number (R0 ) has been determined to be 2-3(2) . This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Syal, Kirtimaan"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281679","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25870","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1663989232501260288,"score":7.979339,"similar":[{"pmid":32238757,"title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).","text":["Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).","Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.","J Microbiol Biotechnol","Ahn, Dae-Gyun","Shin, Hye-Jin","Kim, Mi-Hwa","Lee, Sunhee","Kim, Hae-Soo","Myoung, Jinjong","Kim, Bum-Tae","Kim, Seong-Jun","32238757"],"abstract":["Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19."],"journal":"J Microbiol Biotechnol","authors":["Ahn, Dae-Gyun","Shin, Hye-Jin","Kim, Mi-Hwa","Lee, Sunhee","Kim, Hae-Soo","Myoung, Jinjong","Kim, Bum-Tae","Kim, Seong-Jun"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238757","week":"202014|Mar 30 - Apr 05","doi":"10.4014/jmb.2003.03011","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","coronavirus","outbreak"],"source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663352135440400384,"score":128.88806},{"pmid":32240549,"title":"Pivotal Role of Convalescent Plasma in Managing Emerging Infectious Diseases.","text":["Pivotal Role of Convalescent Plasma in Managing Emerging Infectious Diseases.","Infectious diseases remain one of the top 10 global health threats as announced by the World Health Organization [1]. The emergence of new pathogens for which there is no effective treatment has redrawn the attention to the usefulness of convalescent plasma. Indeed, convalescent plasma can be an alternate and fast therapeutic option in outbreaks of infectious diseases such as Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome (SARS), Chikungunya, Ebola and Zika [2-4]. The recent Coronavirus Disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has prompted not only a search for effective anti-viral treatment and spread control measures, but also a reconsideration of the use of convalescent plasma for COVID-19 treatment [5, 6].","Vox Sang","Wong, H K","Lee, C K","32240549"],"abstract":["Infectious diseases remain one of the top 10 global health threats as announced by the World Health Organization [1]. The emergence of new pathogens for which there is no effective treatment has redrawn the attention to the usefulness of convalescent plasma. Indeed, convalescent plasma can be an alternate and fast therapeutic option in outbreaks of infectious diseases such as Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome (SARS), Chikungunya, Ebola and Zika [2-4]. The recent Coronavirus Disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has prompted not only a search for effective anti-viral treatment and spread control measures, but also a reconsideration of the use of convalescent plasma for COVID-19 treatment [5, 6]."],"journal":"Vox Sang","authors":["Wong, H K","Lee, C K"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240549","week":"202014|Mar 30 - Apr 05","doi":"10.1111/vox.12927","keywords":["COVID-19","SARS-CoV-2","blood center","convalescent plasma","emerging infection"],"source":"PubMed","locations":["Ebola","Chikungunya","Zika"],"topics":["Treatment"],"weight":1,"_version_":1663352135515897858,"score":121.29111},{"pmid":32237160,"title":"Epidemiological analysis of COVID-19 and practical experience from China.","text":["Epidemiological analysis of COVID-19 and practical experience from China.","The rapid spread of the epidemic has aroused widespread concern in the international community. SARS-COV-2 originated from Wuhan's Huanan wholesale seafood market, with bats as the likely original hosts and pangolins as potential intermediate hosts. The current source of the disease is mainly patients infected with SARS-COV-2. Patients in the incubation period may also become sources of infection. The virus is mainly transmitted via respiratory droplets and contact, and the population is generally susceptible. The epidemic has progressed through the local outbreak stage and community transmission stage due to exposure at Wuhan's Huanan wholesale seafood market and is now in the stage of large-scale transmission due to the spread of the epidemic. The basic productive number (R0) at the beginning of the epidemic was 2.2, with an average incubation period of 5.2 days. The proportion of critically ill patients was 23.4%, the mortality rate was lower than those of SARS and MERS, and 96.5% of deaths occurred in Hubei Province, where the outbreak occurred first. Among them, elderly men with underlying diseases had a higher mortality rate. Chinese medical staff have summarized a set of effective strategies and methods in the diagnosis and treatment of this disease that are worthy of reference for their international counterparts. With powerful government intervention and the efforts of Chinese medical staff, China's outbreak has gradually improved. This article is protected by copyright. All rights reserved.","J Med Virol","Ye, Qing","Wang, Bili","Mao, Jianhua","Fu, Junfen","Shang, Shiqiang","Shu, Qiang","Zhang, Ting","32237160"],"abstract":["The rapid spread of the epidemic has aroused widespread concern in the international community. SARS-COV-2 originated from Wuhan's Huanan wholesale seafood market, with bats as the likely original hosts and pangolins as potential intermediate hosts. The current source of the disease is mainly patients infected with SARS-COV-2. Patients in the incubation period may also become sources of infection. The virus is mainly transmitted via respiratory droplets and contact, and the population is generally susceptible. The epidemic has progressed through the local outbreak stage and community transmission stage due to exposure at Wuhan's Huanan wholesale seafood market and is now in the stage of large-scale transmission due to the spread of the epidemic. The basic productive number (R0) at the beginning of the epidemic was 2.2, with an average incubation period of 5.2 days. The proportion of critically ill patients was 23.4%, the mortality rate was lower than those of SARS and MERS, and 96.5% of deaths occurred in Hubei Province, where the outbreak occurred first. Among them, elderly men with underlying diseases had a higher mortality rate. Chinese medical staff have summarized a set of effective strategies and methods in the diagnosis and treatment of this disease that are worthy of reference for their international counterparts. With powerful government intervention and the efforts of Chinese medical staff, China's outbreak has gradually improved. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Ye, Qing","Wang, Bili","Mao, Jianhua","Fu, Junfen","Shang, Shiqiang","Shu, Qiang","Zhang, Ting"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237160","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25813","keywords":["COVID-19","epidemic","mortality","treatment","virus pneumonia"],"source":"PubMed","locations":["Chinese","Wuhan","Hubei","China","Huanan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1663352135527432193,"score":117.467255},{"pmid":32240545,"title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how.","text":["Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how.","Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number CODID-19 cases escalate steeply world-wide. Prior findings in various viral respiratory diseases including SARS-CoV related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2 neutralizing Ab titers in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.","Vox Sang","Tiberghien, Pierre","de Lambalerie, Xavier","Morel, Pascal","Gallian, Pierre","Lacombe, Karine","Yazdanpanah, Yazdan","32240545"],"abstract":["Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number CODID-19 cases escalate steeply world-wide. Prior findings in various viral respiratory diseases including SARS-CoV related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2 neutralizing Ab titers in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution may reduce the frequency of patient deterioration, and thereby COVID-19 mortality."],"journal":"Vox Sang","authors":["Tiberghien, Pierre","de Lambalerie, Xavier","Morel, Pascal","Gallian, Pierre","Lacombe, Karine","Yazdanpanah, Yazdan"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240545","week":"202014|Mar 30 - Apr 05","doi":"10.1111/vox.12926","keywords":["COVID-19","antibody","convalescent plasma","infectious disease","plasma"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135533723649,"score":113.420555},{"pmid":32254064,"title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19.","text":["Deployment of convalescent plasma for the prevention and treatment of COVID-19.","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. \"convalescent\") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. There are numerous examples, where convalescent plasma has been used successfully as post-exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East Respiratory Syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads and improved survival. Globally, blood centers have robust infrastructure to undertake collections and construct inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. .","J Clin Invest","Bloch, Evan M","Shoham, Shmuel","Casadevall, Arturo","Sachais, Bruce S","Shaz, Beth","Winters, Jeffrey L","van Buskirk, Camille","Grossman, Brenda J","Joyner, Michael","Henderson, Jeffrey P","Pekosz, Andrew","Lau, Bryan","Wesolowski, Amy","Katz, Louis","Shan, Hua","Auwaerter, Paul G","Thomas, David","Sullivan, David J","Paneth, Nigel","Gehrie, Eric","Spitalnik, Steven","Hod, Eldad","Pollack, Lewis","Nicholson, Wayne T","Pirofski, Liise-Anne","Bailey, Jeffrey A","Tobian, Aaron Ar","32254064"],"abstract":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. \"convalescent\") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. There are numerous examples, where convalescent plasma has been used successfully as post-exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East Respiratory Syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads and improved survival. Globally, blood centers have robust infrastructure to undertake collections and construct inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. ."],"journal":"J Clin Invest","authors":["Bloch, Evan M","Shoham, Shmuel","Casadevall, Arturo","Sachais, Bruce S","Shaz, Beth","Winters, Jeffrey L","van Buskirk, Camille","Grossman, Brenda J","Joyner, Michael","Henderson, Jeffrey P","Pekosz, Andrew","Lau, Bryan","Wesolowski, Amy","Katz, Louis","Shan, Hua","Auwaerter, Paul G","Thomas, David","Sullivan, David J","Paneth, Nigel","Gehrie, Eric","Spitalnik, Steven","Hod, Eldad","Pollack, Lewis","Nicholson, Wayne T","Pirofski, Liise-Anne","Bailey, Jeffrey A","Tobian, Aaron Ar"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32254064","week":"202015|Apr 06 - Apr 12","doi":"10.1172/JCI138745","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1663450393494945792,"score":111.57056}]}